Azole antifungal agents
The discovery of the antifungal activity of azole compounds represented an important therapeutic advance. Miconazole, ketoconazole, and fluconazole are currently commercially available, and itraconazole has undergone extensive clinical evaluation. Because of its limited activity and toxicity, miconazole has been replaced by newer agents. Ketoconazole has proven useful in therapy for superficial infections and invasive infections caused by the pathogenic fungi. Among its disadvantages are limited absorption in the absence of gastric acid and its potential for drug-drug interactions. Fluconazole is the only azole available as oral and intravenous preparations. Unlike other azoles, it is only minimally metabolized in the liver and largely excreted in the urine as active drug. It is more effective than ketoconazole against superficial candidal infections and is the drug of choice for maintenance therapy for cryptococcal meningitis in patients infected with human immunodeficiency virus. An advantage of itraconazole is its activity against aspergillosis. It is also active against many infections caused by pathogenic fungi. Other azole compounds are at varying stages of preclinical and clinical investigation.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1992 |
|---|---|
| Erschienen: |
1992 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 Suppl 1 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 14 Suppl 1(1992) vom: 14. März, Seite S161-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bodey, G P [VerfasserIn] |
|---|
| Themen: |
304NUG5GF4 |
|---|
| Anmerkungen: |
Date Completed 19.05.1992 Date Revised 09.05.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM012951641 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM012951641 | ||
| 003 | DE-627 | ||
| 005 | 20231221053900.0 | ||
| 007 | tu | ||
| 008 | 231221s1992 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0044.xml |
| 035 | |a (DE-627)NLM012951641 | ||
| 035 | |a (NLM)1314105 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bodey, G P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Azole antifungal agents |
| 264 | 1 | |c 1992 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 19.05.1992 | ||
| 500 | |a Date Revised 09.05.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The discovery of the antifungal activity of azole compounds represented an important therapeutic advance. Miconazole, ketoconazole, and fluconazole are currently commercially available, and itraconazole has undergone extensive clinical evaluation. Because of its limited activity and toxicity, miconazole has been replaced by newer agents. Ketoconazole has proven useful in therapy for superficial infections and invasive infections caused by the pathogenic fungi. Among its disadvantages are limited absorption in the absence of gastric acid and its potential for drug-drug interactions. Fluconazole is the only azole available as oral and intravenous preparations. Unlike other azoles, it is only minimally metabolized in the liver and largely excreted in the urine as active drug. It is more effective than ketoconazole against superficial candidal infections and is the drug of choice for maintenance therapy for cryptococcal meningitis in patients infected with human immunodeficiency virus. An advantage of itraconazole is its activity against aspergillosis. It is also active against many infections caused by pathogenic fungi. Other azole compounds are at varying stages of preclinical and clinical investigation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 650 | 7 | |a Azoles |2 NLM | |
| 650 | 7 | |a Itraconazole |2 NLM | |
| 650 | 7 | |a 304NUG5GF4 |2 NLM | |
| 650 | 7 | |a Miconazole |2 NLM | |
| 650 | 7 | |a 7NNO0D7S5M |2 NLM | |
| 650 | 7 | |a Fluconazole |2 NLM | |
| 650 | 7 | |a 8VZV102JFY |2 NLM | |
| 650 | 7 | |a Ketoconazole |2 NLM | |
| 650 | 7 | |a R9400W927I |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 14 Suppl 1(1992) vom: 14. März, Seite S161-9 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:14 Suppl 1 |g year:1992 |g day:14 |g month:03 |g pages:S161-9 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 Suppl 1 |j 1992 |b 14 |c 03 |h S161-9 | ||